ACP urges balance of benefits, harms, patient preferences for hypertension treatment
The commentary in Annals of Internal Medicine discusses why ACP believes that the evidence does not strongly support pharmacologic initiation and treatment targets of less than 130/80 mm Hg in a broad population of older adults, among other issues.
A commentary from members of ACP's Clinical Practice Guideline Committee discusses the differences between current hypertension guidelines.
In January 2017, ACP and the American Academy of Family Physicians (AAFP) issued a clinical practice guideline for the treatment of hypertension in adults ages 60 years and older.
The guideline differs substantially from the guideline for hypertension in adults issued in November 2017 by the American College of Cardiology (ACC), the American Heart Association (AHA), and nine other health professional organizations (ACP and AAFP were not involved in the development of the ACC/AHA guideline).
Members of ACP's Clinical Practice Guideline Committee have written a commentary that examines these differences. The commentary, which was published online Jan. 23 by Annals of Internal Medicine, discusses why ACP believes that the evidence does not strongly support pharmacologic initiation and treatment targets of less than 130/80 mm Hg in a broad population of older adults, among other issues.